Related Experiment Video
Updated: Feb 11, 2026

Establishment of Gastric Cancer Patient-derived Xenograft Models and Primary Cell Lines
Published on: July 19, 2019
PIK3CA Mutation Analysis in Iranian Patients with Gastric Cancer
Mostafa Iranpour1, Mahyar Nourian1, Sana Saffari2
1AJA Cancer Epidemiology Research and Treatment Center (AJA-CERTC), AJA University of Medical Sciences, Tehran, Iran.
Backgrounda:
Aberrant activation of phosphatidylinositol-3 kinases (PI3K)/AKT/mTOR (mammalian target of rapamycin) pathway is a critical event during gastric cancer progression. Selective function of AKT inhibitor AZD5363 in PI3KCA mutant gastric cancer necessitates the assessment of PI3KCA mutations in these patients.
Methods:
The study included 100 patients with gastric cancer who underwent surgical resection at Imam Reza Hospital, Tehran, Iran, between January 2009 and December 2016. Mutations in codon 1047 of PIK3CA were evaluated by tetra-primer ARMS-PCR and direct sequencing methods.
Results:
We detected p.H1047R and p.H1047L in eight and three samples, respectively. Also, a significant association was found between PIK3CA mutations and lymphatic invasion. Kaplan-Meier analysis demonstrated no significant differences in overall survival between patients with and without mutations.
Conclusion:
Our study detected gain-of-function mutations in exon 20 of PI3KCA gene in 11% of gastric cancer patients. Future studies are needed to assess the mutation rate in other regions of this gene to find eligible patients for targeted therapies.
Insights
Eleven percent of gastric cancer patients harbor PIK3CA mutations, linked to lymphatic invasion but not survival. Further research is needed to identify patients eligible for PI3K/AKT/mTOR pathway targeted therapies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Aberrant activation of the PI3K/AKT/mTOR pathway is crucial in gastric cancer progression.
- Targeted therapies like AZD5363 show selective efficacy in PIK3CA-mutant gastric cancer.
- Assessing PIK3CA mutations is essential for personalized treatment strategies.
Purpose of the Study:
- To evaluate the frequency of PIK3CA mutations in gastric cancer patients.
- To investigate the association between PIK3CA mutations and clinicopathological features, including lymphatic invasion.
- To determine the impact of PIK3CA mutations on overall survival.
Main Methods:
- Analysis of 100 gastric cancer patients who underwent surgical resection.
- Evaluation of PIK3CA mutations in codon 1047 using tetra-primer ARMS-PCR and direct sequencing.
- Kaplan-Meier analysis for overall survival assessment.
Main Results:
- PIK3CA mutations (p.H1047R and p.H1047L) were detected in 11% of patients.
- A significant association was observed between PIK3CA mutations and lymphatic invasion.
- No significant difference in overall survival was found between mutated and non-mutated groups.
Conclusions:
- Gain-of-function mutations in PIK3CA exon 20 occur in 11% of gastric cancer patients.
- Further investigation into other PIK3CA regions is warranted to identify more patients for targeted therapy.
- These findings highlight the importance of molecular profiling for guiding gastric cancer treatment.
Related Concept Videos
Mutations
Mutations
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...
Cancers Originate from Somatic Mutations in a Single Cell
Viral Mutations
Gastric Motility
Peristaltic Waves and Chyme Formation
Upon food entry, the stomach initiates...
Cancer Survival Analysis

